# Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

> **NCT03920267** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 261 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** BMS-986165

## Key facts

- **NCT ID:** NCT03920267
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-03-21
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03920267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03920267, "Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03920267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*